Patent Assignment
Reel/Frame 035552/0202
Change of Name
Recorded: 2015-04-30
Pages: 5
Assignor
BIOGEN IDEC INC.
Executed: 2015-03-23
Assignee
BIOGEN INC.
250 BINNEY STREET, CAMBRIDGE, MASSACHUSETTS, 02142
Covered Properties
(52)
Therapeutic Application of Chimeric and Radiolabeled Antibodies to Human B Lymphocyte Restricted Differentiation Antigen for Treatment of B Cell Lymphoma
Patent:
5,736,137 →
Application:
08/149,099 →
Therapeutic Application of Chimeric and Radiolabeled Antibodies to Human B Lymphocyte Restricted Differentiation Antigen for Treatment of B Cell Lymphoma
Patent:
6,682,734 →
Application:
08/475,813 →
Chimeric and Radiolabeled Antibodies Specific to Human CD20 Antigen and Use Thereof for Treatment of B-Cell Lymphoma
Patent:
6,399,061 →
Application:
08/475,815 →
Recombinant Antibodies for Human Therapy
Patent:
5,756,096 →
Application:
08/476,237 →
Therapeutic Application of Chimeric and Radiolabeled Antibodies to Human B Lymphocyte Restricted Differentiation Antigen for Treatment of B Cell Lymphoma
Patent:
5,776,456 →
Application:
08/476,275 →
Recombinant Antibodies for Human Therapy
Patent:
5,750,105 →
Application:
08/476,349 →
Therapeutic Application of Chimeric and Radiolabeled Antibodies to Human B Lymphocyte Restricted Differentiation Antigen for Treatment of B Cell Lymphoma
Patent:
5,843,439 →
Application:
08/478,967 →
Human B7.1-Specific Primatized Antibodies and Transfectomas Expressing Said Antibodies
Patent:
6,113,898 →
Application:
08/487,550 →
Recombinant Anti-CD4 Antibodies for Human Therapy
Patent:
6,136,310 →
Application:
08/523,894 →
Impaired Dominant Selectable Marker Sequence and Intronic Insertion Strategies for Enhancement of Expression of Gene Product and Expression Vector Systems Comprising Same
Patent:
6,017,733 →
Application:
09/013,092 →
Hydrophobically-Modified Protein Compositions and Methods
Patent:
6,444,793 →
Application:
09/325,256 →
Treatment of Psoriasis Using Anti-B7.1(CD80) Antibodies
Patent:
6,709,654 →
Application:
09/383,916 →
Treatment of Hematologic Malignancies Associated with Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody
Patent:
7,682,612 →
Application:
09/436,347 →
Treatment of Autoimmune Diseases
Patent:
7,820,161 →
Application:
09/564,288 →
Treating Intestinal Inflammation with Anti-CD80 Antibodies That Do Not Inhbit CD80 Binding to Ctla-4
Patent:
7,175,847 →
Application:
09/576,424 →
New Clinical Parameters for Determining Hematologic Toxicity Prior to Radioimmunotheraphy
Patent:
6,451,284 →
Application:
09/625,856 →
Treatment of Aggressive Non-Hodgkins Lymphoma with Anti-CD20 Antibody
Patent:
8,557,244 →
Application:
09/628,187 →
Methods for Treating B Cell Lymphoma Using CD80-Specific Antibodies
Combined Use of Anti-Cytokine Antibodies or Antagonists and Anti-CD20 for Treatment of B Cell Lymphoma
Synergistic Composition and Methods for Treating Neoplastic or Cancerous Growths and for Restoring or Boosting Hematopoiesis
Treatment of B-Cell Associated Diseases Such as Malignances and Autoimmune Diseases Using a Cold Anti-CD20 Antibody/Radiolabeled Anti-CD22 Antibody Combination
Expression and Use of Anti-CD20 Antibodies
Anti-CD20 Antibodies
Tag-72 Specific CH2 Domain Deleted Antibodies
Treatment of B Cell Lymphoma Using Anti-CD80 Antibodies That Do Not Inhibit the Binding of CD80 to Ctla-4
New Clinical Parameters for Deteriming Hematologic Toxicity Prior to Radioimmunotherapy
Expression and Use of Anti-CD20 Antibodies
Method of Purifying Polypeptides by Simulated Moving Bed Chromatography
Use of Depth Filtration in Series with Continuous Centrifugation to Clarify Mammalian Cell Cultures
Anti-CD80 Antibodies
CD80 Specific Antibodies
Nucleic Acids Encoding 7C10 and 16C10 CD80-Specific Antibodies
Host Cells Expressing 7C10 and 16C10 CD80-Specific Antibodies
7C10 and 16C10 CD80-Specific Antibodies
Use of Depth Filtration in Series with Continuous Centrifugation to Clarify Mammalian Cell Cultures
Method for treating joint damage
Application:
11/665,525 →
Publication:
US 2009/0238762
Method of Purifying Polypeptides by Simulated Moving Bed Chromatography
Methods of Producing 7C10 and 16C10 CD80-Specific Antibodies
Methods of Treating Rheumatoid Arthritis with 7C10 and 16C10 CD80-Specific Antibodies
Methods of Inhibiting Il-2 Production by T Cells by Administering 7C10 and 16C10 CD80-Specific Antibodies
Methods of Inducing Immunosuppression by Administering 7C10 and 16C10 CD80-Specific Antibodies
Combination Therapies for B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibody
Use of Chimeric Anti-CD20 Antibody as in Vitro or in Vivo Purging Agent in Patients Receiving Bmt or Pbsc Transplant
Application:
12/100,303 →
Publication:
US 2009/0074760
Treatment of Chronic Lymphocytic Leukemia Using Anti-CD20 Antibodies
Treatment of Vasculitis
Use of Chimeric Anti-CD20 Antibody as in Vitro or in Vivo Purging Agent in Patients Receiving Bmt or Pbsc Transplant
Application:
13/051,054 →
Publication:
US 2011/0165159
Method for Reducing Flu-Like Symptoms Associated with Intramuscular Administration of Interferon Using a Fast Titration Escalating Dosing Regimen
Combination Therapies for B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibody
Application:
13/524,837 →
Publication:
US 2012/0251535
Combination Therapies for B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibodies
Combination Therapies for B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibody
Application:
13/868,753 →
Publication:
US 2013/0273039
Enrichment and Concentration of Select Product Isoforms by Overloaded Bind and Elute Chromatography
Application:
13/885,446 →
Publication:
US 2013/0331554
Treatment of Diffuse Large-Cell Lymphoma with Anti-CD20 Antibody
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jan 14, 1994
From: ANDERSON, DARRELL R.; HANNA, NABIL; LEONARD, JOHN E.; NEWMAN, ROLAND A.
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 006850/0468 →
Assignment of Assignor's Interest
Apr 28, 1994
From: IDEC PHARMACEUTICALS CORPORATION
To: MERRILL LYNCH/MORGAN STANLEY ASSOCIATES, L.P.
Reel/Frame 007121/0587 →
Assignment of Assignor's Interest
Jan 6, 1995
From: IDEC PHARMACEUTICALS CORPORATION
To: SILICON VALLEY BANK
Reel/Frame 007279/0680 →
Assignment of Assignor's Interest
Sep 7, 1995
From: NEWMAN, ROLAND A.; HANNA, NABIL; RAAB, RONALD W.
To: IDEC PHARMACEUTICAL CORPORATION
Reel/Frame 007698/0910 →
Assignment of Assignor's Interest
Nov 6, 1995
From: HANNA, NABIL; NEWMAN, ROLAND A.; REFF, MITCHELL E.
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 007822/0461 →
Assignment of Assignor's Interest
Dec 4, 1995
From: MERRILL LYNCH/MORGAN STANLEY ASSOCIATES, L.P.
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 007735/0672 →
Assignment of Assignor's Interest
Dec 4, 1995
From: MERRILL LYNCH/MORGAN STANLEY ASSOCIATES, L.P.
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 007735/0688 →
Assignment of Assignor's Interest
Dec 4, 1995
From: MERRILL LYNCH/MORGAN STANLEY ASSOCIATES, L.P.
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 007735/0677 →
Assignment of Assignor's Interest
Dec 4, 1995
From: MERRILL LYNCH/MORGAN STANLEY ASSOCIATES, L.P.
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 007735/0669 →
Assignment of Assignor's Interest
May 9, 1996
From: MERRILL LYNCH/MORGAN STANLEY ASSOCIATES, L.P.
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 007934/0284 →
Assignment of Assignor's Interest
May 23, 1996
From: ANDERSON, DARRELL R.; BRAMS, PETER; HANNA, NABIL; SHESTOWSKY, WILLIAM S.
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 007832/0646 →
Assignment of Assignor's Interest
Jan 8, 1998
From: ANDERSON, DARRELL R.; BRAMS, PETER; HANNA, NABIL; SHESTOWSKY, WILLIAM S.
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 008910/0463 →
Release of Security Interest
Nov 1, 1999
From: VENTURE LENDING & LEASING, INC.
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 010340/0869 →
Assignment of Assignor's Interest
Dec 22, 1999
From: WHITE, CHRISTINE A; GRILLO-LOPEZ, ANTONIO J.
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 010464/0829 →
Assignment of Assignor's Interest
Jul 13, 2000
From: ANDERSON, DARRELL R.; HANNA, NABIL; BRAMS, PETER
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 010964/0039 →
Assignment of Assignor's Interest
Sep 5, 2000
From: PEPINSKY, R. BLAKE; GARBER, ELLEN A.; TAYLOR, FREDERICK R.; GALDES, ALPHONSE
To: BIOGEN, INC.
Reel/Frame 011091/0227 →
Assignment of Assignor's Interest
Sep 5, 2000
From: PORTER, JEFFREY
To: ONTOGENY, INC.
Reel/Frame 011083/0607 →
Assignment of Assignor's Interest
Oct 10, 2000
From: GRILLO-LOPEZ, ANTONIO J.
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 011184/0942 →
Assignment of Assignor's Interest
Oct 10, 2000
From: CURD, JOHN G.; KUNKEL, LORI A.
To: GENENTECH, INC.
Reel/Frame 011197/0263 →
Assignment of Assignor's Interest
Jan 5, 2001
From: WHITE, CHRISTINE; GRILLO-LOPEZ, ANTONIO
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 011413/0479 →
Assignment of Assignor's Interest
Oct 9, 2001
From: WHITE, CHRISTINE
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 012248/0940 →
Assignment of Assignor's Interest
Nov 5, 2001
From: ANDERSON, DARRELL R.; HANNA, NABIL; LEONARD, JOHN E.; NEWMAN, ROLAND A.
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 012297/0365 →
Assignment of Assignor's Interest
Jul 17, 2002
From: RAESTETTER, WILLIAM; WHITE, CHRISTINE A.
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 013095/0931 →
Merger
Jan 16, 2004
From: CREATIVE BIOMOLECULES, INC.; ONTOGENY, INC.; REPROGENESIS, INC.
To: BIOGEN, INC.
Reel/Frame 014894/0753 →
Change of Name
Aug 6, 2004
From: IDEC PHARMACEUTICALS CORPORATION
To: BIOGEN IDEC INC.
Reel/Frame 015044/0873 →